

CONTENTS

	The Platinum Hall of Fame 10.1016/j.eururo.2019.10.021	e153
Platinum Opinions	Prostate Cancer: Quo Vadis? <i>C.J. Logothetis, A. Aparicio, F. Koinis, P.G. Corn, E. Efstathiou</i> Utility measures are urgently needed for clinical application of new, more sensitive diagnostics to reduce the risk of excessive intervention.	709
	Male Life Expectancy is Still Inferior to That of Women: Urologists Must Refine and Develop the Concept of Men's Health <i>T. Tharakan, A. Salonia, S. Minhas, on behalf of the European Association of Urology Working Group on Male Sexual and Reproductive Health</i> Urologists can bridge the gender gap in life expectancy through the promotion of a holistic and streamlined approach to men's health that incorporates optimisation of lifestyle factors (smoking cessation, weight loss, diet) and comorbidities (treatment of hypertension, hypercholesterolaemia, and hypogonadism) and offers cancer screening.	712
Brief Correspondence	Augmented Bladder Tumor Detection Using Deep Learning <i>E. Shkoljar, X. Jia, T.C. Chang, D. Trivedi, K.E. Mach, M.Q.-H. Meng, L. Xing, J.C. Liao</i> We developed a deep learning algorithm (CystoNet) for computer-augmented detection of bladder cancer during cystoscopy. In a prospective validation cohort, CystoNet demonstrated high sensitivity and specificity for the detection of bladder tumors.	714
Platinum Priorities Original Articles and Reviews together with the Full Length Editorials	Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer <i>A.P. Hoyle, A. Ali, N.D. James, A. Cook, C.C. Parker, J.S. de Bono, G. Attard, S. Chowdhury, W.R. Cross, D.P. Dearnaley, C.D. Brawley, C. Gilson, F. Ingleby, S. Gillissen, D.M. Aebersold, R.J. Jones, D. Matheson, R. Millman, M.D. Mason, A.W.S. Ritchie, M. Russell, H. Douis, M.K.B. Parmar, M.R. Sydes, N.W. Clarke, on behalf of the STAMPEDE Investigators</i> A significant treatment benefit is observed in men with metastatic hormone-naïve prostate cancer treated with androgen deprivation therapy combined with abiraterone acetate and prednisolone, irrespective of being designated as having a "low" or a "high" risk by the current treatment criteria. This consistent result applies to all efficacy outcome measures.	EU★ACME 719
Prostate Cancer	The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data <i>C.J. Sweeney, H. Beltran</i>	729
	Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy <i>E. De Bleser, B.A. Jereczek-Fossa, D. Pasquier, T. Zilli, N. Van As, S. Siva, A. Fodor, P. Dirix, A. Gomez-Iturriaga, F. Trippa, B. Detti, G. Ingrosso, L. Triggiani, A. Bruni, F. Alongi, D. Reyniers, G. De Meerleer, A. Surgo, K. Loukili, R. Miralbell, P. Silva, S. Chander, N.G. Di Muzio, E. Maranzano, G. Francolini, A. Lancia, A. Tree, C.L. Deantoni, E. Ponti, G. Marvaso, E. Goetghebeur, P. Ost</i> In treating nodal oligorecurrent prostate cancer, elective nodal radiotherapy reduces nodal relapse compared with stereotactic body radiotherapy. However, elective nodal radiotherapy was associated with higher toxicity.	732

	<p>Salvage Radiotherapy for Nodal Oligorecurrent Prostate Cancer: A Step Towards Predictive Criteria for Metastasis-Directed Therapy in Prostate Cancer? 740</p> <p><i>N.B. Desai, K. Courtney, R.M. Subramaniam, J.A. Cadeddu</i></p>
	<p>Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry 743</p> <p><i>C.W. Jeong, J.E. Cowan, J.M. Broering, R.M.T. ten Ham, L.S. Wilson, P.R. Carroll, M.R. Cooperberg</i></p> <p>We elicited utilities among the Cancer of the Prostate Strategic Urologic Research Endeavor cohort using the standard gamble method. These utilities were much higher than the previously reported values. The results indicate substantial human resilience, with most of the patients adapting to their health conditions even if they experience incomplete functional recovery.</p>
	<p>Resilience of men and the gap hypothesis of quality of life: Health utility outcome measurement in prostate cancer 752</p> <p><i>A.W. Glaser</i></p>
Kidney Cancer	<p>Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights 754</p> <p><i>M.I. Carlo, A.A. Hakimi, G.D. Stewart, G. Bratslavsky, J. Brugarolas, Y.-B. Chen, W.M. Linehan, E.R. Maher, M.J. Merino, K. Offit, V.E. Reuter, B. Shuch, J.A. Coleman</i></p> <p>In the last few years, there have been significant advances in our knowledge about the familial kidney cancer syndromes, with updated recommendations on work-up and management. Additionally, there are more recently described familial kidney cancer syndromes that may be under-recognised.</p>
	<p>Is Knowledge Power or Is Ignorance Bliss: Screening and Management of Familial Renal Cell Carcinoma Syndromes 765</p> <p><i>M. Strother, A. Kutikov</i></p>
Voiding Dysfunction	<p>Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment  767</p> <p><i>C. Gratzke, C. Chapple, E.R. Mueller, D. Robinson, C. Rolland, D. Staskin, M. Stoelzel, R.v. Maanen, E. Siddiqui</i></p> <p>A review of studies reporting the efficacy/safety of two antimuscarinics or a 3-adrenoreceptor agonist plus an antimuscarinic for overactive bladder symptoms found that mirabegron plus solifenacin was effective and well tolerated. Limited data for dual antimuscarinic therapy suggested benefits for moderate-to-severe symptoms.</p>
	<p>Combination Therapy for Overactive Bladder: Should We Define Refractoriness? 780</p> <p><i>B. Padilla-Fernández, D.M. Castro-Díaz</i></p>
Reviews	<p>Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis  782</p> <p><i>S.A. Niglio, R. Jia, J. Ji, S. Ruder, V.G. Patel, A. Martini, J.P. Sfakianos, K.E. Marqueen, N. Waingankar, R. Mehrazin, P. Wiklund, W.K. Oh, M. Mazumdar, B.S. Ferket, M.D. Galsky</i></p> <p>Restricted mean survival time estimates may be used to benchmark survival outcomes and inform future trial design. Programmed death-1 and programmed death ligand-1 blockade in patients with platinum-resistant metastatic urothelial cancer yield comparable survival outcomes.</p>
Urothelial Cancer	
Prostatic Disease	<p>EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study) 790</p> <p><i>T.B.L. Lam, S. MacLennan, P.-P.M. Willemse, M.D. Mason, K. Plass, R. Shepherd, R. Baanders, C.H. Bangma, A. Bjartell, A. Bossi, E. Briers, A. Briganti, K.T. Buddingh, J.W.F. Catto, M. Colecchia, B.W. Cox, M.G. Cumberbatch, J. Davies, N.F. Davis, M. De Santis, P. Dell'Oglio, A. Deschamps, J.F. Donaldson, S. Egawa, C.D. Fankhauser, S. Fanti, N. Fossati, G. Gandaglia, S. Gillissen, N. Grivas, T. Gross, J.P. Grummet, A.M. Henry, A. Ingels, J. Irani, M. Laldas, M. Liew, D.W. Lin, L. Moris, M.I. Omar, K.H. Pang, C.C. Paterson, R. Renard-Penna, M.J. Ribal, M.J. Roobol, M. Roupêt, O. Rouvière, G. Sancho Pardo, J. Richenberg, I.G. Schoots, J.P.M. Sedelaar, P. Stricker, D. Tilki, S. Vahr Lauridsen, R.C.N. van den Bergh, T. Van den Broeck, T.H. van der Kwast, H.G. van der Poel, G.J.L.H. van Leenders, M. Varma, P.D. Violette, C.J.D. Wallis, T. Wiegel, K. Wilkinson, F. Zattoni, J.M.O. N'Dow, H. Van Poppel, P. Cornford, N. Mottet</i></p>

Surgery in Motion

The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations has developed comprehensive consensus statements for deferred active treatment for localised prostate cancer covering all domains, aimed at guiding and informing routine clinical practice and research.

Posterior, Anterior, and Periurethral Surgical Reconstruction of Urinary Continence Mechanisms in Robot-assisted Radical Prostatectomy: A Description and Video Compilation of Commonly Performed Surgical Techniques 814

A.N. Vis, H.G. van der Poel, A.E.C. Ruiter, J.C. Hu, A.K. Tewari, B. Rocco, V.R. Patel, S. Razdan, J.A. Nieuwenhuijzen

We describe and video-illustrate the most frequently performed pelvic reconstructive techniques in robot-assisted radical prostatectomy aimed at lowering stress urinary incontinence. Many of the procedures report a benefit with respect to early continence, which seems to diminish with longer follow-up.

Original Articles

Prostate Cancer

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial 823

P.-L. Kellokumpu-Lehtinen, M. Hjälm-Eriksson, C. Thellenberg-Karlsson, L. Åström, L. Franzen, A.-S. Fransson, M.J. Leskinen, M. Zeke, T. Huttunen, C. Ginman, on behalf of the Investigators of the Scandinavian Prostate Cancer Study No. 13

In a randomised setting, intermediate- or high-risk prostate cancer patients treated with adjuvant chemotherapy with docetaxel following radical radiotherapy and androgen deprivation therapy (ADT) did not show improved biochemical disease-free survival compared with those who underwent radical radiotherapy and ADT alone. More adverse events occurred with the combined treatment, but there were fewer prostate-specific antigen relapses than were estimated to occur in both groups.

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers 831

E.C. Page, E.K. Bancroft, M.N. Brook, M. Assel, M. Hassan Al Battat, S. Thomas, N. Taylor, A. Chamberlain, J. Pope, H.N. Raghallaigh, D.G. Evans, J. Rothwell, L. Maehle, E.M. Grindedal, P. James, L. Mascarenhas, J. McKinley, L. Side, T. Thomas, C. van Asperen, H. Vasen, L.A. Kiemeny, J. Ringelberg, T.D. Jensen, P.J.S. Osther, B.T. Helfand, E. Genova, R.A. Oldenburg, C. Cybulski, D. Wokolorczyk, K.-R. Ong, C. Huber, J. Lam, L. Taylor, M. Salinas, L. Feliubadaló, J.C. Oosterwijk, W. van Zelst-Stams, J. Cook, D.J. Rosario, S. Domchek, J. Powers, S. Buys, K. O'Toole, M.G.E.M. Ausems, R.K. Schmutzler, K. Rhiem, L. Izatt, V. Tripathi, M.R. Teixeira, M. Cardoso, W.D. Foulkes, A. Aprikian, H. van Randeraad, R. Davidson, M. Longmuir, M.W.G. Ruijs, A.T.J.M. Helder van den Enden, M. Adank, R. Williams, L. Andrews, D.G. Murphy, D. Halliday, L. Walker, A. Liljegren, S. Carlsson, A. Azzabi, I. Jobson, C. Morton, K. Shackleton, K. Snape, H. Hanson, M. Harris, M. Tischkowitz, A. Taylor, J. Kirk, R. Susman, R. Chen-Shtoyerman, A. Spigelman, N. Pachter, M. Ahmed, T. Ramon y Cajal, J. Zgajnar, C. Brewer, N. Gadea, A.F. Brady, T. van Os, D. Gallagher, O. Johannsson, A. Donaldson, J. Barwell, N. Nicolai, E. Friedman, E. Obeid, L. Greenhalgh, V. Murthy, L. Copakova, S. Saya, J. McGrath, P. Cooke, K. Rønlund, K. Richardson, A. Henderson, S.H. Teo, B. Arun, K. Kast, A. Dias, N.K. Aaronson, A. Ardern-Jones, C.H. Bangma, E. Castro, D. Dearnaley, D.M. Eccles, K. Tricker, J. Eyfjord, A. Falconer, C. Foster, H. Gronberg, F.C. Hamdy, V. Stefansdottir, V. Khoo, G.J. Lindeman, J. Lubinski, K. Axcrona, C. Mikropoulos, A. Mitra, C. Moynihan, G. Rennert, M. Suri, P. Wilson, T. Dudderidge, The IMPACT Study Collaborators, J. Offman, Z. Kote-Jarai, A. Vickers, H. Lilja, R.A. Eeles

We demonstrate that after 3 yr of prostate-specific-antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening.

Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer 834

M.-E. Taplin, E.S. Antonarakis, K.J. Ferrante, K. Horgan, B. Blumenstein, F. Saad, J. Luo, J.S. de Bono

The prevalence of circulating tumor cells expressing androgen receptor V7 in castration-resistant prostate cancer naïve to abiraterone or enzalutamide is low and associated with aggressive disease. Treatment approaches other than available second-generation androgen axis inhibitors should be considered.

Kidney Cancer



Response of Primary Renal Cell Carcinoma to Systemic Therapy 852

D. Bossé, X. Lin, R. Simantov, A.-K.A. Lalani, I. Derweesh, S.L. Chang, T.K. Choueiri, R.R. McKay

Systemic therapy can lead to primary tumor shrinkage in metastatic renal cell carcinoma. Of the patients treated with anti-vascular endothelial growth factor therapy, 28% achieved an objective response of their primary tumor. Individuals with International Metastatic Renal Cell Carcinoma Database Consortium poor-risk disease did not derive benefit from cytoreductive nephrectomy.

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium 861

S. Dudani, J. Graham, J.C. Wells, Z. Bakouny, S.K. Pal, N. Dizman, F. Donskov, C. Porta, G. de Velasco, A. Hansen, M. Iafora, B. Beuselinck, U.N. Vaishampayan, L.A. Wood, E. Liow, F. Yan, T. Yuasa, G.A. Bjarnason, T.K. Choueiri, D.Y.C. Heng

Using the International Metastatic Renal-cell Carcinoma Database Consortium database, we reviewed 188 patients with metastatic renal-cell carcinoma who received first-line ipilimumab and nivolumab (ipi-nivo) versus immuno-oncology/vascular endothelial growth factor (VEGF) combinations. There were no significant differences in first-line outcomes between groups. Response rates to second-line VEGF-based treatments were higher in patients who received ipi-nivo.

Words of Wisdom



Re: Increased Production and Reduced Urinary Buffering of Acid in Uric Acid Stone Formers is Ameliorated by Pioglitazone 868

D.G. Assimos

Re: Comparison of Population-based Observational Studies with Randomized Trials in Oncology 869

C.J.D. Wallis, Z. Klaassen

Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer 870

C.S. Voskuilen, M.S. van der Heijden, B.W.G. van Rhijn

Re: EAU Guidelines: Prostate Cancer 2019 871

M.C. Sighinolfi, B. Rocco

Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer 872

G. Butcher, H. Howard, N. Sathianathan, J.W.F. Catto, D.G. Murphy

Re: Urodynamics Useless in Female Stress Urinary Incontinence? Time for Some Sense—A European Expert Consensus 873

A. Braga, G. Caccia, M. Soligo

Research Letter



Testing the Feasibility of SentiMag/Sienna+ for Detecting Inguinal Sentinel Nodes in Penile Cancer (SentiPen): An eUROGEN and National Cancer Research Institute Trial 874

P. Cleaveland, M. Lau, A. Parnham, B. Murby, D. Ashworth, P. Manohoran, B. Taylor, J. Bell, P. Najran, P. Oliveira, J. Shanks, V. Sangar

Congress Calendar e162

Acknowledgement to Reviewers e164

The illustration on the cover of this issue is taken from the article by Eugene Shkolyar, Xiao Jia, Timothy C. Chang, Dharati Trivedi, Kathleen E. Mach, Max Q.-H. Meng, Lei Xing, Joseph C. Liao, Augmented Bladder Tumor Detection Using Deep Learning, which is published on pp. 714–718 of this issue.

